Optimizing Therapy for Endometrial Cancer: Recent Data Highlights

Discover the latest advancements and challenges in the treatment of endometrial cancer, from therapeutic breakthroughs to the importance of diverse clinical trial enrollment, presented by leading experts in gynecologic oncology.

EP. 1: Changing Landscape of Endometrial Cancer: Incidence and Classification

October 30th 2023

Dive into the evolving landscape of endometrial cancer, including rising incidence, classification, racial disparities, and emerging modalities, as discussed by experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD.

EP. 2: Optimal Workup Strategies in Advanced Endometrial Cancer

October 30th 2023

Explore the case of a 67-year-old patient with recurrent endometrial cancer, highlighting the importance of MMR testing, NGS, and emerging treatment options in today's landscape.

EP. 3: Factors in Frontline Treatment Decision Making for Endometrial Cancer

November 6th 2023

Key factors influencing frontline treatment choices in endometrial cancer, including biomarker status, comorbidities, guidelines, and patient preferences, with a focus on the evolving landscape of therapies.

EP. 4: Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors

November 6th 2023

Insight into the typical response to first-line chemotherapy in advanced endometrial cancer and the clinical factors that influence treatment outcomes, with a focus on improving therapies for this high-risk cohort.

EP. 5: Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy

November 13th 2023

Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, discuss the prevalence of patients with recurrent endometrial cancer, challenges in responding to chemotherapy, and the potential for improved treatment options in the second-line setting.

EP. 6: Treatment Choices for Recurrent dMMR Endometrial Cancer

November 13th 2023

Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies.

EP. 7: HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment

November 20th 2023

The role of HER2 status and targeted therapy with trastuzumab in advanced endometrial cancer, emphasizing the need for effective management of cardiac toxicities and comorbidities.

EP. 8: Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab

November 20th 2023

Learn about the factors that influence the choice between chemotherapy re-challenge and the combination of lenvatinib and pembrolizumab for endometrial cancer treatment in the context of clinical data.

EP. 9: Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab

November 27th 2023

Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.

EP. 10: Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status

November 27th 2023

Explore the groundbreaking shift in frontline treatment for endometrial cancer, driven by recent data from trials like RUBY and GY018, highlighting the significant impact of checkpoint inhibitors in patients with mismatch repair deficiency.

NEXT PAGE
PREVIOUS PAGE